Product Catalog
Subscriptions
Get mail on new products
Advion Signs Lilly Deal, Will Open Bioanalytical Lab
Advion BioServices plans to open a 22,000-sq.-ft. drug discovery bioanalytical lab in the Purdue Research Park in Indianapolis. The lab is expected to be fully operational by the end of May 2011.
Advion’s primary focus is to provide high-quality, later stage bioanalytical drug development services as required by global regulatory agencies, including the FDA. The new Indianapolis facility will focus on the earlier stage, drug discovery bioanalytical services, evaluating how a potential drug is absorbed and metabolized in experimental models. Many of these services are data-generation activities required for clinical testing preparation.
Advion has also entered into a new, multi-year contract with Lilly to provide a variety of these services to be conducted at the new facility. As part of the agreement, Lilly will transition its drug discovery bioanalytical capability to Advion. All Lilly employees impacted will have the opportunity to join Advion. Financial terms were not disclosed.
“Drug discovery bioanalytical services in Indianapolis are a strategic complement to the regulated drug development bioanalytical services in our Ithaca, NY and Manassas, VA laboratories. Advion has always upheld the highest standards of scientific rigor and looks forward to establishing a center-of-excellence for discovery bioanalytical services in Indianapolis,” said Tom Kurz, president of Advion BioServices, Inc.
Advion’s primary focus is to provide high-quality, later stage bioanalytical drug development services as required by global regulatory agencies, including the FDA. The new Indianapolis facility will focus on the earlier stage, drug discovery bioanalytical services, evaluating how a potential drug is absorbed and metabolized in experimental models. Many of these services are data-generation activities required for clinical testing preparation.
Advion has also entered into a new, multi-year contract with Lilly to provide a variety of these services to be conducted at the new facility. As part of the agreement, Lilly will transition its drug discovery bioanalytical capability to Advion. All Lilly employees impacted will have the opportunity to join Advion. Financial terms were not disclosed.
“Drug discovery bioanalytical services in Indianapolis are a strategic complement to the regulated drug development bioanalytical services in our Ithaca, NY and Manassas, VA laboratories. Advion has always upheld the highest standards of scientific rigor and looks forward to establishing a center-of-excellence for discovery bioanalytical services in Indianapolis,” said Tom Kurz, president of Advion BioServices, Inc.